Clinical trials: Overweight or Obesity; Type 2 Diabetes
Obesity or Overweight, Type 2 Diabetes
A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, and PK of AZD5004 compared with placebo in Chinese participants with overweight/obesity with or without T2DM.
- Trial name
- NCT06988553
- Testing
- AZD5004
- Where
- 6 sites in China
- Volunteers
- 45 people
- Sponsor
- Eccogene
Overweight and Obesity, Cardiovascular Diseases
Study Consortium for Evaluation of RNPC Program in Obese and Overweight Patients (SCOOP-RNPC)
The investigators hypothesize that weight loss obtained with the French RNPC weight reduction program is beneficial for the general health of overweight/obese patients in the medium term.
- Conditions
- Overweight and Obesity, Cardiovascular Diseases, Metabolic Disease, Diabete Type 2
- Trial name
- SCOOP-RNPC (NCT05857319)
- Testing
- Nutritional Psycho-Behavioral Reeducation Program
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Groupe Éthique et Santé
Overweight or Obesity, Type2 Diabetes Mellitus
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study…
- Trial name
- NCT05762471
- Testing
- GSBR-1290
- Where
- 4 sites in United States
- Volunteers
- 142 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity, Diabetes Mellitus, Type 2
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
This is a prospective cohort study evaluating the efficacy, safety, and tolerability of tirzepatide under real-world conditions in the Paraguayan population.
- Trial name
- REAL-TIRZEPY (NCT07588438)
- Testing
- Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.)
- Where
- Paraguay
- Volunteers
- 160 people
- Sponsor
- Las Rías Medical Center
Obesity, Overweight
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2…
- Trial name
- NCT06643728
- Testing
- Bimagrumab, Tirzepatide
- Where
- 12 sites in United States
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Obesity and Overweight
A First-in-human Study of HCR-188 in Overweight or Obese Otherwise Healthy Volunteers Without Type 2 Diabetes
This is a first-in-human study evaluating the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of single and multiple doses of HCR-188 administered as subcutaneous injection(s).
- Trial name
- NCT06845943
- Testing
- HCR-188
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Helicore Biopharma, Inc.
Obesity, Type 2 Diabetes Mellitus
Metformin in Overweight Type 2 Diabetes Mellitus
The study included 102 overweight type 2 diabetes mellitus patients with a body mass index (BMI) of more than 25 in an open label study.
- Trial name
- NCT00922194
- Testing
- Extended Release Metformin
- Where
- India
- Volunteers
- 102 people
- Sponsor
- Era's Lucknow Medical College
Type 2 Diabetes, Obesity
Registry Observing EndoBarrier® Treatment Outcomes in Subjects With Type 2 Diabetes and/or Obesity
The purpose of the registry was to observe the safety and effectiveness outcomes for subjects treated with the EndoBarrier in the post market setting where the product had Conformité Européene (CE mark) regulatory approval and in…
- Trial name
- NCT03072901
- Testing
- EndoBarrier Gastrointestinal Liner
- Volunteers
- 244 people
- Sponsor
- Morphic Medical Inc.
Diabetes Type 2, Overweight or Obesity
Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life
The goals of this randomized trial is to learn: 1. If the Thrive AI Health app will help adults improve their everyday habits (diet, exercise, and sleep). 2.
- Trial name
- NCT07376655
- Testing
- App
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Yale University
Diabete Mellitus, Obesity & Overweight
Comparing Two Low-Carbohydrate Diets With a Standard Diet in Type 2 Diabetes
Type 2 diabetes is often accompanied by high blood triglycerides and excess weight, and diet plays a central role in managing these conditions together.
- Conditions
- Diabete Mellitus, Obesity & Overweight, Hypertriglyceridaemia
- Trial name
- NCT07801378
- Testing
- High-Protein Low-Carbohydrate Diet, High-Fat Low-Carbohydrate Diet, Standard diet
- Volunteers
- 168 people
- Sponsor
- National Nutrition and Food Technology Institute
Overweight, Obesity
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- STEP7 (NCT04251156)
- Testing
- Semaglutide
- Where
- 33 sites in Brazil, China and 2 more
- Volunteers
- 375 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D).
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT07868354
- Testing
- Tirzepatide, Zenagamtide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Obesity
An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers
The purpose of this study is to evaluate the safety and tolerance of multiple intravenous (through a vein) doses of trodusquemine (MSI-1436) in obese or overweight, type 2 diabetics.
- Trial name
- NCT00806338
- Testing
- Trodusquemine (MSI-1436)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Genaera Corporation
Obesity, Overweight
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program.
- Trial name
- SURMOUNT-3 (NCT04657016)
- Testing
- Tirzepatide
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 579 people
- Sponsor
- Eli Lilly and Company
Obesity and Obesity-related Medical Conditions
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
- Trial name
- NCT06924320
- Testing
- MET233 and MET097, MET097
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus, Overweight
Diacerein on Insulin Secretion in Diabetes
Aim. To assess the effect of interleukin 1β (IL-1β) and tumor necrosis factor α (TNFα) inhibition with diacerein administration on insulin secretion and metabolic control of drug-naïve patients with type 2 diabetes mellitus…
- Conditions
- Type 2 Diabetes Mellitus, Overweight, Obesity
- Trial name
- NCT01298882
- Testing
- Diacerein
- Where
- Mexico
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with…
- Trial name
- NCT01272232
- Testing
- liraglutide
- Where
- 161 sites in United States, France and 11 more
- Volunteers
- 846 people
- Sponsor
- Novo Nordisk A/S
Diabete Type 2, Obesity
Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled parallel group study of HU6 and placebo in subjects who are overweight or obese with T2D. The study will be conducted in 4 stages.
- Trial name
- NCT06104358
- Testing
- HU6
- Where
- United States
- Sponsor
- Rivus Pharmaceuticals, Inc.
Obesity Type 2 Diabetes Mellitus
Chinese, Overweight or Obesity, Real-World Registry Study
This study will enroll 10,000 patients with obesity, with the participation of approximately 50 medical institutions nationwide.
- Trial name
- NCT07525037
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Chinese PLA General Hospital
Metabolism and Nutrition Disorder, Obesity
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.
- Trial name
- SCALE™ Insulin (NCT02963922)
- Testing
- Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 5 more
- Volunteers
- 396 people
- Sponsor
- Novo Nordisk A/S